Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Cash from Operations (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Cash from Operations for 6 consecutive years, with 10592730.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations fell 117.02% to 10592730.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 25616066.0, a 48.54% decrease, with the full-year FY2024 number at 19148067.0, down 5.88% from a year prior.
  • Cash from Operations was 10592730.0 for Q3 2025 at Inhibikase Therapeutics, down from 5574231.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 2020498.0 in Q3 2021 to a low of 10592730.0 in Q3 2025.
  • A 5-year average of 4692197.63 and a median of 4246516.0 in 2021 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: plummeted 145828.38% in 2021, then skyrocketed 35.25% in 2024.
  • Inhibikase Therapeutics' Cash from Operations stood at 4095817.0 in 2021, then rose by 13.17% to 3556374.0 in 2022, then grew by 3.2% to 3442431.0 in 2023, then tumbled by 55.28% to 5345575.0 in 2024, then tumbled by 98.16% to 10592730.0 in 2025.
  • Per Business Quant, the three most recent readings for IKT's Cash from Operations are 10592730.0 (Q3 2025), 5574231.0 (Q2 2025), and 4103530.0 (Q1 2025).